Abstract
All common contributing factors to epilepsy such as trauma, malignancies and infections are accompanied by different levels of central nervous system inflammation that in turn have been associated with the occurrence of seizure. Emerging data from human brain tissue and experimental models of epilepsy support the proposed involvement of inflammation in epilepsy. Key mediators of this process include, among others: interleukin (IL) -1β, IL-6, tumor necrosis factor-α, adhesion molecules and component of complement. Recent advances suggest the involvement of specific inflammatory pathways in the pathogenesis of seizures in patients with pharmacoresistant temporal lobe epilepsy, highlighting the potential for new therapeutic strategies. This review provides an overview of the current knowledge on the relationship between inflammatory mediators and epilepsy. We also describe experimental and clinical evidence of inflammation in epilepsy with special emphasis on clinical aspects once the epileptogenic focus has been resected. Further insight into the complex role of inflammation in epileptogenesis may provide new treatment options.
Keywords: Epilepsy, inflammatory mediators, IL-1β, IL-6, TNF-α, neuroinflammation, temporal lobe epilepsy
Current Pharmaceutical Design
Title:Inflammatory Mediators in Epilepsy
Volume: 19 Issue: 38
Author(s): Lourdes Lorigados Pedre, Lilia M Morales Chacón, Sandra Orozco Suárez, Nancy Pavón Fuentes, Bárbara Estupiñán Díaz, Teresa Serrano Sánchez, Iván García Maeso and Luisa Rocha Arrieta
Affiliation:
Keywords: Epilepsy, inflammatory mediators, IL-1β, IL-6, TNF-α, neuroinflammation, temporal lobe epilepsy
Abstract: All common contributing factors to epilepsy such as trauma, malignancies and infections are accompanied by different levels of central nervous system inflammation that in turn have been associated with the occurrence of seizure. Emerging data from human brain tissue and experimental models of epilepsy support the proposed involvement of inflammation in epilepsy. Key mediators of this process include, among others: interleukin (IL) -1β, IL-6, tumor necrosis factor-α, adhesion molecules and component of complement. Recent advances suggest the involvement of specific inflammatory pathways in the pathogenesis of seizures in patients with pharmacoresistant temporal lobe epilepsy, highlighting the potential for new therapeutic strategies. This review provides an overview of the current knowledge on the relationship between inflammatory mediators and epilepsy. We also describe experimental and clinical evidence of inflammation in epilepsy with special emphasis on clinical aspects once the epileptogenic focus has been resected. Further insight into the complex role of inflammation in epileptogenesis may provide new treatment options.
Export Options
About this article
Cite this article as:
Lorigados Pedre Lourdes, Morales Chacón Lilia M, Orozco Suárez Sandra, Pavón Fuentes Nancy, Estupiñán Díaz Bárbara, Serrano Sánchez Teresa, García Maeso Iván and Rocha Arrieta Luisa, Inflammatory Mediators in Epilepsy, Current Pharmaceutical Design 2013; 19 (38) . https://dx.doi.org/10.2174/1381612811319380009
DOI https://dx.doi.org/10.2174/1381612811319380009 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Design, Synthesis of 6-Substituted-pyrido[3,2-d]pyridazine Derivatives with Anticonvulsant Activity
Medicinal Chemistry Diagnosing and Treating Depression in Older and Oldest Old
Current Pharmaceutical Design Gap Junctions as Therapeutic Targets in Brain Injury Following Hypoxia- Ischemia
Recent Patents on CNS Drug Discovery (Discontinued) The Treatment of Painful Diabetic Neuropathy
Current Diabetes Reviews P2Y Receptors: Focus on Structural, Pharmacological and Functional Aspects in the Brain
Current Medicinal Chemistry Catatonia: A Brief Update
Current Psychiatry Reviews Nano-medicine Improving the Bioavailability of Small Molecules for the Prevention of Neurodegenerative Diseases
Current Pharmaceutical Design Role of Resveratrol and its Analogues in the Treatment of Neurodegenerative Diseases: Focus on Recent Discoveries
CNS & Neurological Disorders - Drug Targets Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis
Current Medicinal Chemistry Regulation of miRNA Processing and miRNA Mediated Gene Repression in Cancer
MicroRNA Editorial [Hot Topic: Calcium Regulatory Proteins as Therapeutic Targets (Guest Editor: Livia C. Hool)]
Current Drug Targets Shining Light on an mGlu5 Photoswitchable NAM: A Theoretical Perspective
Current Neuropharmacology PET and SPECT Imaging of the NMDA Receptor System: An Overview of Radiotracer Development
Mini-Reviews in Medicinal Chemistry On the Relationship Between the Light/Dark Cycle, Melatonin and Oxidative Stress
Current Pharmaceutical Design Pharmacological Approaches of Binge Drinking
Current Pharmaceutical Design Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Role of the GABAA Receptor in Anxiety: Evidence from animal models, molecular and clinical psychopharmacology, and brain imaging studies
Current Neuropharmacology Genes, Blame and Loss of Control: is there a Place in Criminal Law for a ‘Genetic Defense’?
Recent Advances in DNA & Gene Sequences (Discontinued) Parkinson Disease Genetics: A "Continuum" from Mendelian to Multifactorial Inheritance
Current Molecular Medicine Extracellular Vesicles in Glioblastoma: Role in Biological Processes and in Therapeutic Applications
Current Cancer Drug Targets